Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aminoglutethimide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 19/20 | 1.00 |
| ▸ | CYP11A1 known ✓ | P05108 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminoglutethimide SCHEMBL4306 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL7728932 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL116988 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL28457203 | 0.98 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL28119771 | 0.97 | CYP19A1 (0.94) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL28329350 | 0.94 | CYP19A1 (0.89) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL11699322 | 0.93 | CYP19A1 (0.86) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL28196944 | 0.93 | CYP19A1 (0.86) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL27862969 | 0.89 | CYP19A1 (0.80) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL159173 | 0.88 | CYP19A1 (0.78) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5661014-A | Chiral compounds and their resolution synthesis using enantioselective esterases | CHIROSCIENCE LIMITED (GB) | 1997-08-26 | — | — | US | claimed |
| CN-1151731-A | Chiral compounds and their resolution | CHIROSCIENCE LTD (GB) | 1997-06-11 | — | — | CN | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-117561249-A | Cereblon binding compounds, compositions thereof, and methods for their use in therapy | 细胞基因公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| EP-2038253-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007138242-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-5661014-A | Chiral compounds and their resolution synthesis using enantioselective esterases | CHIROSCIENCE LIMITED (GB) | 1997-08-26 | — | — | US | disclosed |
| CN-1151731-A | Chiral compounds and their resolution | CHIROSCIENCE LTD (GB) | 1997-06-11 | — | — | CN | disclosed |
| EP-0763023-A1 | CHIRAL COMPOUNDS AND THEIR RESOLUTION | Chiroscience Limited (GB) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995032947-A1 | CHIRAL COMPOUNDS AND THEIR RESOLUTION | CHIROSCIENCE LIMITED (GB) | 1995-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | CYP19A1 4073/4885CYP11A1 3595/4885CYP3A4 1505/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | CYP19A1 4073/4885CYP11A1 3595/4885CYP3A4 1505/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CYP19A1 169/4885CYP11A1 90/4885CYP3A4 209/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | CYP19A1 4073/4885CYP11A1 3595/4885CYP3A4 1505/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | CYP19A1 169/4885CYP11A1 90/4885CYP3A4 209/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | CYP19A1 2444/4885CYP11A1 4010/4885CYP3A4 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.